BioXcel Therapeutics

paper stacks documents
Pharma

Despite misconduct at trial site, BioXcel touts audit's findings

The FDA previously uncovered evidence of forged emails and trial misconduct in the company's phase 3 Alzheimer's disease agitation study.
Zoey Becker Oct 25, 2023 11:04am
diversity in clinical trials clinical trial study research healthcare doctor patient

Failed endpoint, forged emails mar BioXcel's Alzheimer's data

Jun 29, 2023 11:04am